Health ❯ Healthcare

Oncology

Cancer Treatment Breast Cancer Lung Cancer Cancer Research Clinical Trials Patient Care Pediatric Oncology Cancer Treatments Chemotherapy Tumor Biology

Immunotherapy Before 3 p.m. Linked to Longer Survival in Small Cell Lung Cancer

Researchers link the timing effect to circadian rhythms, urging prospective confirmation.

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

Early Trial Finds Virtual Diet-and-Exercise Support Eases Lymphoma Chemo Side Effects

Pirtobrutinib Outperforms Ibrutinib on Response, Shows Early PFS Edge in First Head‑to‑Head CLL/SLL Trial

Swedish Study Ties Lower Ipilimumab Dose to Longer Survival and Less Toxicity in Advanced Melanoma

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

ECOG-ACRIN Review Finds Black AML Patients Have Worse Survival Independent of Cytogenetics

EndRAD Phase 2 Finds Non-TBI Conditioning Matches Outcomes in MRD-Negative Young B-ALL

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

Pliant’s PLN-101095 With Keytruda Shows Early Responses in PD-1–Refractory Solid Tumors

FDA Installs Tracy Beth Hoeg as Acting CDER Director as Pazdur Files Retirement

FDA Grants Full Approval to Jaypirca for Relapsed CLL/SLL After Covalent BTK Therapy

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

FDA Accepts Sonrotoclax NDA, Grants Priority Review for Relapsed Mantle Cell Lymphoma

Global Consortium Publishes PRO Standards for Cancer Trials and Launches Implementation Toolkit

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

FDA Approves Perioperative Keytruda–Padcev for Cisplatin‑Ineligible Muscle‑Invasive Bladder Cancer

City of Hope Completes $1.5 Billion Irvine Cancer Hospital, First Patients Arrive Dec. 1

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma